Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE plus tislelizumab for conversion to resection in early/intermediate unresectable HCC
ChiCTR2100052539Phase 2Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Shanghai General Hospital. Primary endpoint: R0 resection rate. Started Jan 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100052539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052539.